Save on Teclistamab-CQYV with Coupons, Discounts & Savings Programs

Teclistamab-CQYV is available as a subcutaneous injection that contains 30 mg/3 mL (10 mg/mL) or 153 mg/1.7 mL (90 mg/mL.

• Teclistamab-CQYV is a monoclonal antibody that is used to treat advanced multiple myeloma in adults who’ve already tried at least four other therapies

Teclistamab-CQYV is a monoclonal antibody. More specifically, it’s called a bispecific T-cell engager, or BiTE therapy. This medication works by binding to 2 targets: it grabs onto both the multiple myeloma cancer cells and immune cells in your body called T-cells. By bringing these cells together, Teclistamab-CQYV makes it easier for the T cells to attack the cancer cells. In addition, when Teclistamab-CQYV binds to both cells, the multiple myeloma cancer cells can’t grow or spread as well.

• Your provider will determine your dose of Teclistamab-CQYV based on your body weight. This medication is injected under the skin by a healthcare provider, typically in a hospital or clinic setting
• Starting dose (“step-up” dosing): During your first week of treatment, your provider will raise your dose over the course of a week
• Day 1 dose: 0.06 mg/kg injected once
• Day 4 dose: 0.3 mg/kg injected once
• Day 7 dose: 1.5 mg/kg injected once
• Maintenance dose: Starting a week after the last dose, your provider will give you 1.5 mg/kg injected under the skin once a week

Teclistamab-CQYV is a safe and effective treatment when used for FDA licensed indications. However, like all medications, they may give you unwanted side effects. You should always discuss potential side effects with your physician to ensure the medication is suitable and right for you.

Common side effects of Teclistamab-CQYV:

• Lower blood cell counts
• Fever
• Cytokine release syndrome
• Low protein (albumin) levels in blood
• Muscle pain
• Higher liver enzymes in blood
• Electrolyte changes in blood
• Skin reaction around injection site
• Tiredness
• Respiratory infections
• Nausea
• Headache
• Diarrhea

Serious side effects are rare with Teclistamab-CQYV. Contact your healthcare provider immediately if you experience any of the following.

• Cytokine release syndrome: Fever, trouble breathing, chills, low blood pressure, changes in heart rhythm, headache
• Serious nervous system problems: headache, confusion,
• difficulty speaking, difficulty writing, seizures
  Serious liver problems: yellow skin, yellow eyes, swelling in the belly
• Serious infection: fever, cough, weakness, tiredness, body aches, chills, painful rash, blisters, stomach pain

The following medications may interact with Teclistamab-CQYV:

• Teclistamab-CQYV causes release of cytokines that may suppress activity of cytochrome P450 (CYP) enzymes, resulting in increased exposure of CYP substrates. The highest risk of drug-drug interaction is expected to occur from initiation of Teclistamab-CQYV step-up dosing schedule up to 7 days after the first treatment dose and during and after CRS. Monitor for toxicity or concentrations of drugs that are CYP substrates where minimal concentration changes may lead to serious adverse reactions. Adjust the dose of the concomitant CYP substrate drug as needed

Various FDA-approved generic manufacturers

IBased on its mechanism of action, Teclistamab-CQYV may cause fetal harm when administered to a pregnant woman. If you can become pregnant you should use effective contraception during treatment with Teclistamab-CQYV and for 5 months after the last dose.

• Tecvayli